Antimicrobial Susceptibility Testing

Antimicrobial Susceptibility Testing

Global Antimicrobial Susceptibility Testing Market to Reach US$4.6 Billion by 2030

The global market for Antimicrobial Susceptibility Testing estimated at US$3.6 Billion in the year 2023, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Manual Antimicrobial Susceptibility Testing Products, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Automated Laboratory Instruments segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$970.2 Million While China is Forecast to Grow at 6.8% CAGR

The Antimicrobial Susceptibility Testing market in the U.S. is estimated at US$970.2 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$992.2 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Antimicrobial Susceptibility Testing Market - Key Trends & Drivers Summarized

Antimicrobial Susceptibility Testing (AST) is an essential process in microbiology that determines the effectiveness of antibiotics against specific bacterial pathogens. This testing is critical for guiding appropriate antibiotic therapy, helping clinicians choose the most effective treatment for infections. AST is performed using various methods, including disk diffusion, broth microdilution, and automated systems. Each method involves exposing the bacteria to different concentrations of antibiotics and observing their growth patterns. The results indicate whether the bacteria are susceptible, intermediate, or resistant to the antibiotics tested, which is vital information for treating infections and combating antibiotic resistance.

The importance of AST has increased with the rise of antibiotic-resistant bacteria, which pose a significant public health threat. Accurate and timely susceptibility testing helps in the stewardship of existing antibiotics by ensuring their appropriate use, thereby slowing the spread of resistance. Advances in AST technology have improved the speed and accuracy of results. Automated systems and molecular methods, such as PCR and next-generation sequencing, allow for rapid detection of resistance genes and provide more detailed information about bacterial pathogens. These technological advancements have made AST more efficient, enabling faster clinical decision-making and better patient outcomes.

The growth in the antimicrobial susceptibility testing market is driven by several factors. The increasing prevalence of antibiotic-resistant infections is a primary driver, necessitating more frequent and comprehensive testing. Government initiatives and regulations aimed at controlling the spread of resistance and improving antibiotic use are also contributing to market growth. Additionally, the growing demand for rapid and accurate diagnostic tools in healthcare settings has spurred the adoption of advanced AST methods. The expansion of clinical laboratories and the rising investment in research and development further support the market. These factors, combined with the ongoing need for effective infection control measures, ensure a strong growth trajectory for the antimicrobial susceptibility testing market.

Select Competitors (Total 52 Featured) -

• Accelerate Diagnostics, Inc.
• Alifax S.r.l.
• Becton Dickinson, and Company
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Biotron Limited
• Bruker Corp.
• Creative Diagnostics
• Danaher Corporation
• ELITech Group
• F. Hoffmann-La Roche AG
• HiMedia Laboratories Pvt. Ltd.
• Liofilchem S.r.l.
• Mast Group Ltd.
• Merck KGaA
• MP Biomedicals LLC
• Q-linea AB
• QuantaMatrix, Inc.
• Resistell AG
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.